New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
10:00 EDTVRTX, MEGGF, VMI, KRA, VIAB, PBR, HOG, EVEP, COH, DISCK, CTRPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Coach (COH) downgraded at BofA/Merrill... Ctrip.com (CTRP) downgraded to Outperform from Strong Buy at Raymond James... Discovery Communications (DISCK) downgraded to Neutral from Buy at BTIG... EV Energy (EVEP) downgraded to Hold from Buy at Wunderlich... Harley-Davidson (HOG) downgraded at KeyBanc... Kraton Performance (KRA) downgraded to Neutral from Outperform at Credit Suisse... Meggitt (MEGGF) downgraded to Underweight from Neutral at JPMorgan... Petrobras (PBR) downgraded to Equal Weight from Overweight at Morgan Stanley... Valmont (VMI) downgraded to Neutral from Outperform at Wedbush... Vertex (VRTX) downgraded to Neutral from Buy at H.C. Wainwright... Viacom (VIAB) downgraded to Neutral from Buy at BTIG.
News For COH;CTRP;DISCK;EVEP;HOG;KRA;MEGGF;PBR;VMI;VRTX;VIAB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 23, 2015
09:38 EDTVRTXVertex shares defended at CRT Capital
Subscribe for More Information
09:37 EDTVRTXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
09:30 EDTPBRHSBC raises exposure to Russia, Brazil, others, Reuters says
Subscribe for More Information
09:28 EDTVRTXOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTVRTXLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:47 EDTVRTXVertex says VX-661, ivacaftor generally well tolerated in 12-week Phase 2 study
Vertex Pharmaceuticals announced data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation. The study evaluated two doses of VX-661 in combination with ivacaftor. The primary endpoint of the study was safety. The study showed that the combination regimen was generally well tolerated, and all patients completed 12 weeks of treatment. The most common adverse events were pulmonary exacerbation, which occurred in 38% of all patients who received VX-661 and 44% of those who received placebo, and cough, which occurred in 33% of all patients who received VX-661 and 39% of those who received placebo. Secondary endpoints evaluated the effect of the combination on lung function, and the mean within-group absolute improvement from baseline in ppFEV1 for those who received 100 mg of VX-661 in combination with ivacafto was 4.4 and 3.0 percentage points at week 4 and through 12 weeks of treatment, respectively. Consistent with prior Phase 2 studies that evaluated 4 weeks of treatment with VX-661 in combination with ivacaftor, this study showed a rapid improvement in lung function within four weeks of treatment, and after patients completed treatment, lung function returned to baseline. These safety and efficacy data, together with other data from multiple previously completed Phase 2 studies of VX-661, support Vertex’s ongoing Phase 3 program of VX-661 in combination with ivacaftor. The Phase 3 program is evaluating VX-661 in combination with ivacaftor and consists of four Phase 3 studies, including a study in people with two copies of the F508del mutation that began enrollment in February. The other three studies will enroll people with CF who have one copy of the F508del mutation and a second mutation that is either a gating mutation, residual function mutation or a mutation that results in minimal CFTR function.
March 20, 2015
16:36 EDTCTRPCtrip.com reports Q4 EPS (19c), consensus (28c)
Subscribe for More Information
16:22 EDTCTRPOn The Fly: Closing Wrap
Subscribe for More Information
11:59 EDTCTRPCtrip.com price target raised to $75 from $67 at HSBC
Subscribe for More Information
10:18 EDTCTRPOptions with decreasing implied volatility
Options with decreasing implied volatility: NKTR FOLD RUSL RSX ORCL GES CTRP SLXP WSM SPXS
10:07 EDTCTRPHigh option volume stocks
Subscribe for More Information
09:24 EDTCTRPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Ctrip.com (CTRP), up 20.1%... Rally Software (RALY), up 17.3%... Nike (NKE), up 5.2%... Darden Restaurants (DRI), up 4.3%... Cheetah Mobile (CMCM), up 3.6%. ALSO HIGHER: Prothena (PRTA), up 40.2% after reporting positive results from Phase 1 study of PRX002... Viggle (VGGL), up 26.9% after confirming receipt of offer from chairman and CEO Robert Sillerman... Intercept Pharmaceuticals (ICPT), up 8.5% after announcing new data analyses from FLINT trial... Biogen Idec (BIIB), up 9.7% after presenting positive interim results from study of aducanumab... Pier 1 Imports (PIR), up 5.2% after being upgraded to Outperform from Perform at Oppenheimer... JinkoSolar (JKS), up 2.8% after announcing that it will supply 75 MWdc of its PV solar modules to Red Horse 2 project and following a strategic collaboration agreement with DuPont (DD). DuPont is up just under 1%. DOWN AFTER EARNINGS: AK Steel (AKS), down 6.8%... Youku Tudou (YOKU), down 4.9%... Tiffany (TIF), down 3.3%. ALSO LOWER: Macerich (MAC), down 7.7% after Simon makes $95.50 per share "best and final" offer.
07:16 EDTCTRPCtrip.com price target raised to $70 from $64 at Brean Capital
Brean Capital raised its price target to $70 from $64 on Ctrip.com citing its secular growth story, aggressive investments, and proven strong execution. Brean Capital reiterated its Buy rating on Ctrip.com shares.
06:06 EDTCTRPStocks with implied volatility above IV index mean; CTRP BIIB
Subscribe for More Information
March 19, 2015
18:05 EDTCTRPCtrip.com sees Q1 revenue RMB 1.01B-RMB 1.03B
14:31 EDTCTRPCtrip.com technical comments ahead of earnings
Subscribe for More Information
07:33 EDTKRAKraton developing reorganization strategy with Bain, Bloomberg says
Subscribe for More Information
07:32 EDTPBRPetrobras volatility elevated as shares near 12-year low
Subscribe for More Information
March 18, 2015
16:00 EDTPBROptions Update; March 18, 2015
iPath S&P 500 VIX Short-Term Futures down 1.20 to 26.10. Option volume leaders: AAPL RAD PBR TWTR FB TSLA CLF BP MGM according to Track Data.
09:23 EDTVIABVerizon may launch mobile TV service as soon as June, Bloomberg says
Verizon (VZ) has secured mobile television streaming rights with Viacom (VIA, VIAB) and DreamWorks Animation (DWA) and plans to start a mobile video streaming service as early as June, according to Bloomberg, citing a person familiar with the matter. Verizon plans to have programming from ABC (DIS), NBC (CMCSA), CBS (CBS) and Fox (FOXA) as part of the service, the report added. The Fly notes that Verizon has publicly confirmed previously that it plans to launch such a service, but has not provided many details to date.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use